Latest Headlines

  1. Coming Soon To Big Pharma: Disruption Innovation

    When 250+ top-tier pharmaceutical thought leaders get together for 2 days of debate, discussion and discourse, some fur is sure to fly.

  2. PolyPid Announces Issuance Of New U.S. Patent For Doxycycline Sustained Release Compositions

    PolyPid, a clinical stage pharmaceutical company and developer of PLEX, a protected drug reservoir platform for effective localized, controlled and prolonged drug delivery, recently announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,173,976, covering compositions for sustained and/or controlled release of doxycycline.

  3. Immune Pharmaceuticals Announces Enrollment Of The First Patient Into The Phase 2 Clinical Trial With Bertilimumab In Ulcerative Colitis

    Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

  4. AMA Calls For Ban On Direct To Consumer Advertising Of Prescription Drugs And Medical Devices

    Responding to the billions of advertising dollars being spent to promote prescription products, physicians at the Interim Meeting of the American Medical Association (AMA) recently adopted new policy aimed at driving solutions to make prescription drugs more affordable.

  5. Final Call For Innovators: Pharmapack Europe Awards 2016

    Pharmapack Europe (#pharmapackeu), organised by UBM, is issuing a final call for entries to the 2016 Pharmapack Awards. Now in its 15th edition, the awards continue to showcase technologies from across the industry.

  6. ISPE Announces Recipients Of 2015 International Honor Awards At Annual Meeting

    International Society for Pharmaceutical Engineering (ISPE) announced the recipients of the 2015 International Honor Awards at the society’s Annual Meeting in Philadelphia, PA.

  7. Werum IT Solutions Advances Standardized Track & Trace Solutions For Packaging Serialization In The Pharmaceutical Industry

    Werum IT Solutions is expanding its integrating role in the field of packaging serialization and aggregation, and is extending its independent Track & Trace solution by a connection to OCS Checkweighers equipment.

  8. Bespak And Aesica Unveil New Single Source Supply Chain Solution For Drug Delivery Device And Pharmaceutical Manufacturing Services

    Novel business model set to streamline and speed products to market whilst reducing cost and complexity of development Bespak, a world leading drug delivery device design, development and manufacturing company and Aesica, a global pharmaceutical contract development and manufacturing organisation (CDMO), are today unveiling the industry’s first single source supply chain solution for drug delivery products incorporating formulation development, device design and development, drug and device manufacture, fill/finish and secondary packaging. 

  9. New Haven Pharmaceuticals: Study Shows DURLAZA (aspirin) Extended-Release Capsules Delivers Sustained Antiplatelet Effects For Full 24 hours

    New Haven Pharmaceuticals, Inc. recently announced new study data that shows the company’s FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.

  10. Melanoma Research Alliance Hails FDA's Approval Of Combination Therapy For Advanced Melanoma

    The Melanoma Research Alliance (MRA) hails the approval of yet another treatment for melanoma by the U.S. Food & Drug Administration (FDA). The latest approved therapy is the combination of Roche's vemurafenib (Zelboraf) and cobimetinib (Cotellic) for the treatment of patients with advanced metastatic melanoma.